ASX Share rice
Tue 04 Aug 2020 - 02:41:pm (Sydney)

DXB Share Price

DIMERIX LIMITEDDXBPharmaceuticals, Biotechnology & Life Sciences

DXB Company Information

Name:

Dimerix Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

425 Smith Street Fitzroy VIC Australia 3065

Phone:

61 8 9388 8290

Exec. Chairman:

Dr. James Howard Williams M.B.A., BSc (Hons), Ph.D., MBA, GAICD

CEO, MD & Director:

Dr. Nina Webster Ph.D., M.IP.Law, MBA

CFO & Company Sec.:

Mr. Hamish George B.Com., C.A.

Chief Scientific Advisor:

Mr. Kevin Donald George Pfleger BA (Hons), MA, Ph.D.

Bus. Devel. Officer:

Ms. Elizabeth McCall B.Com., L.L.B., LLB., B.Juris, B.Com(Hons), GAICD

Company Overview:

Dimerix Limited, a clinical stage biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. Its lead product candidate is DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis. The company is headquartered in Fitzroy, Australia.

DXB Share Price Information

Shares Issued:

181.53M

Market Capitalisation:

$85.32M

Revenue (TTM):

$1.19M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.018

Operating Margin (TTM):

$-3.67

Return On Assets (TTM):

$-0.58

Return On Equity (TTM):

$-1.01

Quarterly Revenue Growth (YOY):

-0.993

Gross Profit(TTM):

$1.45M

Diluted Earnings Per Share (TTM):

$-0.027

DXB CashFlow Statement

CashFlow Date:

2019-06-30

Investments:

$-6,906

Change To Liabilities:

$354.94K

Total Cashflow From Investing Activities:

$-6,906

Net Income:

$-2,886,221

Total Cash From Operating Activities:

$-2,750,802

Depreciation:

$4.68K

Change To Account Receivables:

$-371,471

Capital Expenditures:

$6.91K

DXB Income Statement

Income Date:

2019-06-30

Income Before Tax:

$-2,886,221

Net Income:

$-2,886,221

Gross Profit:

$1.45M

Operating Income:

$-4,333,611

Total Revenue:

$1.45M

Total Operating Expenses:

$4.33M

DXB Balance Sheet

Balance Sheet Date:

2019-06-30

Total Liabilities:

$737.77K

Total Stockholder Equity:

$4.20M

Other Current Liabilities:

$18.39K

Total Assets:

$4.94M

Common Stock:

$20.47M

Retained Earnings:

$-16,941,680

Cash:

$3.56M

Total Current Liabilities:

$737.77K

Property - Plant & Equipment:

$2.62K

Net Tangible Assets:

$4.20M

Total Current Assets:

$4.94M

Net Receivables:

$1.27M

Short-Term Investments:

$2.62K

Accounts Payable:

$416.82K

Non Currrent Assets (Other):

$2.62K

Short-Term Investments:

$2.62

Non Current Liabilities Total:

$0

DXB Share Price History

DXB News

29 Jul, 2020
Dimerix reported excellent results from the clinical trial of drug DMX-200 aimed at rare kidney disease focal segmental glomerulosclerosis (FSGS)
04 May, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, Dimerix (ASX:DXB...
05 Feb, 2020
If you want to compound wealth in the stock market, you can do so by buying an index fund. But if you pick the right...
07 Nov, 2019
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
23 Sep, 2019
If you want to know who really controls Dimerix Limited (ASX:DXB), then you'll have to look at the makeup of its share...
08 Aug, 2019
If you're interested in Dimerix Limited (ASX:DXB), then you might want to consider its beta (a measure of share price...